Sabby Management’s Cardiol Therapeutics CRDL Stock Holding History

Sabby Management’s Portfolio CRDL Stock Details CRDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-99,440	Closed	-$184K	–	160
2021 Q4	$184K	Buy	+99,440	New	+$275K	0.03%	136

Other funds holding CRDL

MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

VIA

Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Sabby Management's CRDL Position: Q1 2022 in Review

Sabby Management sold out of Cardiol Therapeutics (CRDL) in Q1 2022, closing a stake of 99,440 shares — an estimated $184K sold.

Sabby Management first reported a position in CRDL in Q4 2021 and held it in 1 quarter. The position peaked at $184K in Q4 2021. 28 funds tracked by Wall St. Rank hold CRDL as of Q1 2022.

Sabby Management reported no remaining Cardiol Therapeutics position as of Q1 2022 after selling out during the quarter.
Sabby Management sold 99,440 Cardiol Therapeutics shares in Q1 2022, an estimated $184K.
Sabby Management first reported a position in Cardiol Therapeutics in Q4 2021 and held it in 1 quarter.
Sabby Management's Cardiol Therapeutics position peaked at $184K in Q4 2021.
28 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q1 2022.

Based on Sabby Management's 13F filing for Q1 2022, filed 16 May 2022.